China Shineway Pharmaceutical Group Limited provided consolidated earnings guidance for the six months ended June 30, 2023. Based on the preliminary assessment of the Group's unaudited consolidated management accounts, the Group's profit attributable to the owners of the Company for the six months ended 30 June 2023 (the "Period") is expected to increase by approximately 45% to 50% as compared with that for the corresponding period of last year (the corresponding period of 2022: RMB 331,123,000). The expected increase in the profit attributable to the owners of the Company for the Period is mainly attributable to (i) the increase in overall sales revenue of the Group of approximately 32% and (ii) the increase in gross profit and net profit margins as compared with that for the corresponding period of last year.

During the Period, sales revenue of all dosage forms increased, and among them sales revenue of injection products and TCM formula granules products increased by approximately 37% and 34% respectively.